T-Heart
Development of a solution for patients suffering from tricuspid regurgitation, a serious, untreated heart valve disease .
T-Heart
Founded in 2018, T-Heart is an innovative company developing a novel and differentiated minimally invasive transcatheter tricuspid valve replacement system for the treatment of severe tricuspid regurgitation (TR)..
TR is a progressive condition in which blood is forced back through the tricuspid valve, potentially leading to heart failure and death. .
T-Heart’s patented innovation solves the specific anatomical problems of the tricuspid valve with a simple one-step procedure, while managing the right ventricular load with a physiologically sized valve. T-Heart’s minimally invasive technology addresses this unmet clinical need and has a market potential estimated at $3Bn per year.
TR is a progressive condition in which blood is forced back through the tricuspid valve, potentially leading to heart failure and death. .
T-Heart’s patented innovation solves the specific anatomical problems of the tricuspid valve with a simple one-step procedure, while managing the right ventricular load with a physiologically sized valve. T-Heart’s minimally invasive technology addresses this unmet clinical need and has a market potential estimated at $3Bn per year.
News
